Inventor · disambiguated record
Brian J. Czerniecki
Also filed as: CARTER LEGAL REPRESENTATIVE LAURA · CZERNIECKI BRIAN · CZERNIECKI BRIAN J
8 granted patents·12 pending applications·239 citations·filing 1994–2023
86Inventor score
Files withCZERNIECKI BRIAN J5H LEE MOFFITT CANCER CT & RES5UNIV PENNSYLVANIA3US HEALTH3COHEN PETER A1
Top patents by PatentIndex Score
20 records- 0190US5643786AMethod for isolating dendritic cellsUS HEALTH·Filed 1995·Granted Jul 1, 1997·123 cites·7 claims
- 0279US11660330B2Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapyH LEE MOFFITT CANCER CT & RES·Filed 2020·Granted May 30, 2023·1 cites·6 claims
- 0379US6010905AMethod for inducing monocytes to exhibit the phenotype of activated myeloid dendritic cellsUS HEALTH·Filed 1997·Granted Jan 4, 2000·60 cites·32 claims
- 0479US5814295ADetermination of lymph nodes enriched in tumor reactive cells their proliferation and their use in adoptive cellular therapyUNIV OHIO STATE RES FOUND·Filed 1994·Granted Sep 29, 1998·49 cites·48 claims
- 0571US8247227B2Dendritic cell precursorsCOHEN PETER A·Filed 2007·Granted Aug 21, 2012·5 cites·7 claims
- 0665US12201719B2Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapyH LEE MOFFITT CANCER CENTER AND RES INSTITUTE INC A FLORIDA NON PROFIT CORPORATION·Filed 2023·Granted Jan 21, 2025·0 cites·14 claims
- 0765US2024209316A1System and method of preparing and storing activated mature dendritic cellsUNIV PENNSYLVANIA·Filed 2023·Application pending·0 cites
- 0863US2021163573A1Identification of immunogenic mhc class ii peptides for immune-based therapyUNIV PENNSYLVANIA·Filed 2020·Application pending·0 cites
- 0960US2024299544A1Cancer therapies comprising peptide loaded cxcr3- and ccr5-inducing dendritic cells and chemokine modulatory agentsHEALTH RESEARCH INC·Filed 2022·Application pending·0 cites
- 1058US2023390345A1Combination therapy comprising her-2-dc1 vaccine, a probiotic, and semaphorinH LEE MOFFITT CANCER CT & RES·Filed 2021·Application pending·0 cites
- 1158US2024009232A1Combination therapy comprising her-2-dc1 vaccine and a probioticH LEE MOFFITT CANCER CT & RES·Filed 2021·Application pending·0 cites
- 1257US10829538B2Identification of immunogenic MHC class II peptides for immune-based therapyUNIV PENNSYLVANIA·Filed 2016·Granted Nov 10, 2020·0 cites·3 claims
- 1357US2024091359A1Novel esr1 derived peptides and uses thereof for neoantigen therapyH LEE MOFFITT CANCER CT & RES·Filed 2022·Application pending·0 cites
- 1445US2022370496A1Her3 pulsed dc1 therapyH LEE MOFFITT CANCER CT & RES·Filed 2020·Application pending·0 cites
- 1539US2017261508A1Methods for monitoring cd4+ t-helper type 1 response in cancer and immune restorationCZERNIECKI BRIAN J·Filed 2017·Application pending·0 cites
- 1635US2017216421A1Manufacturing of multi-dose injection ready dendritic cell vaccines, combination therapies for blocking her2 and her3, and estrogen receptor positive her2 breast receptor positive her2 breast cancer therapyCZERNIECKI BRIAN J·Filed 2016·Application pending·0 cites
- 1734US2013183343A1System and Method of Preparing and Storing Activated Mature Dendritic CellsCZERNIECKI BRIAN J·Filed 2011·Application pending·0 cites
- 1833US2018171294A1In vitro artificial lymph node method for sensitization and expansion of t cells for therapy and epitope mappingCZERNIECKI BRIAN J·Filed 2016·Application pending·0 cites
- 1932US6358736B1Method for increasing the antigen presenting ability of leukemia cellsUS HEALTH·Filed 1999·Granted Mar 19, 2002·1 cites·31 claims
- 2032US2015323547A1Methods for monitoring cd4+ t-helper type 1 response in cancer and immune restorationCZERNIECKI BRIAN J·Filed 2015·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →